{
    "clinical_study": {
        "@rank": "48685", 
        "arm_group": [
            {
                "arm_group_label": "0.2mg triptorelin and 500 IU hCG", 
                "arm_group_type": "Experimental", 
                "description": "Patients were triggered with 0.2mg triptorelin and 500 IU hCG"
            }, 
            {
                "arm_group_label": "0.2mg triptorelin and 1000 IU hCG", 
                "arm_group_type": "Experimental", 
                "description": "Patients were triggered with 0.2mg triptorelin and 1000 IU hCG"
            }
        ], 
        "brief_summary": {
            "textblock": "Gonadotropin releasing hormone (GnRH) agonist is sufficient for triggering final oocyte\n      maturation in GnRH antagonist protocol and can significantly reduce incidence of ovarian\n      hyperstimulation syndrome (OHSS) in high-risk patients.\n\n      However, lower oocyte yield was reported in patients with lower luteinizing hormone (LH)\n      level post trigger with single injection of GnRH agonist, which might be related to the\n      shorter duration and lower amount of LH induced by GnRH agonist.\n\n      Our aim is to study dual trigger with GnRH agonist and human chorionic gonadotropin (hCG)\n      for preventing OHSS and maintaining clinical outcome in high risk patients who receive\n      controlled ovarian stimulation in GnRH antagonist protocol."
        }, 
        "brief_title": "Dual Trigger to Reduce Ovarian Hyperstimulation Syndrome", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Infertility and at High Risk of OHSS", 
        "condition_browse": {
            "mesh_term": [
                "Infertility", 
                "Ovarian Hyperstimulation Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  patients with polycystic ovarian syndrome\n\n          -  patients with polycystic ovarian morphology on ultrasound\n\n          -  patients who previously experienced an ovarian stimulation cycle, with a high\n             response to gonadotrophins\n\n        Exclusion Criteria:\n\n          -  patients undergoing coasting\n\n          -  patients with past ovarian surgery"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "40 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02022228", 
            "org_study_id": "Dual Trigger"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "0.2mg triptorelin and 500 IU hCG", 
                    "0.2mg triptorelin and 1000 IU hCG"
                ], 
                "description": "0.2 mg triptorelin, ih", 
                "intervention_name": "triptorelin", 
                "intervention_type": "Drug", 
                "other_name": "triptorelin: Diphereline"
            }, 
            {
                "arm_group_label": "0.2mg triptorelin and 1000 IU hCG", 
                "description": "1000 IU hCG, im", 
                "intervention_name": "hCG", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "0.2mg triptorelin and 500 IU hCG", 
                "description": "500IU hCG, im", 
                "intervention_name": "hCG", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Chorionic Gonadotropin", 
                "Triptorelin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Ovarian Hyperstimulation Syndrome", 
            "Luteinizing Hormone", 
            "Polycystic Ovarian Syndrome", 
            "Ovarian Yield", 
            "Ovarian Maturity", 
            "Gonadotropin Releasing Hormone Agonist", 
            "Human Chorionic Gonadotropin"
        ], 
        "lastchanged_date": "December 20, 2013", 
        "location": {
            "contact": {
                "email": "chensl_92@163.com", 
                "last_name": "Shi-Ling Chen, M.D., Ph.D.", 
                "phone": "+86-20-62787604"
            }, 
            "facility": {
                "address": {
                    "city": "Guangzhou", 
                    "country": "China", 
                    "state": "Guangdong", 
                    "zip": "510515"
                }, 
                "name": "Center for Reproductive Medicine, Department of Gynecology and Obstetrics, Nanfang Hospital, Southern Medical University"
            }, 
            "investigator": {
                "last_name": "Shi-Ling Chen, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Dual Trigger With GnRH Agonist and Human Chorionic Gonadotropin for Final Oocyte Maturation in Patients at High Risk of Ovarian Hyperstimulation Syndrome in GnRH Antagonist Protocol", 
        "overall_contact": {
            "email": "chensl_92@163.com", 
            "last_name": "Shi-Ling Chen, M.D., Ph.D.", 
            "phone": "+86-20-62787604"
        }, 
        "overall_official": {
            "affiliation": "Nanfang Hospital of Southern Medical University", 
            "last_name": "Shi-Ling Chen, M.D., Ph.D.", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "clinical pregnancy rate per transfer cycle", 
                "safety_issue": "Yes", 
                "time_frame": "1month post embryo transfer"
            }, 
            {
                "measure": "numbers of patients having OHSS", 
                "safety_issue": "Yes", 
                "time_frame": "2 weeks post trigger with dual GnRHa"
            }, 
            {
                "description": "Oocyte yield was defined as the ratio of the total number of collected oocytes to the number of follicles measuring \u226510 mm on the day of oocyte retrieval.", 
                "measure": "oocyte yield", 
                "safety_issue": "Yes", 
                "time_frame": "oocyte retrieval day (34 to 38 hours post trigger with GnRHa and hCG)"
            }, 
            {
                "description": "Oocyte maturity was defined as the ratio of metaphase II (MII) oocytes to the number of collected oocytes in the patients undergoing with intracytoplasmic sperm injection (ICSI).", 
                "measure": "Oocyte maturity", 
                "safety_issue": "Yes", 
                "time_frame": "24 hours post oocyte retrieval day"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02022228"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Nanfang Hospital of Southern Medical University", 
            "investigator_full_name": "Chenshiling", 
            "investigator_title": "Professor, M.D., Ph.D.", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "serum luteinizing hormone level 12 hours post trigger", 
                "safety_issue": "Yes", 
                "time_frame": "12 hours post trigger"
            }, 
            {
                "measure": "serum hCG level 12 hours post trigger", 
                "safety_issue": "Yes", 
                "time_frame": "12 hours post trigger"
            }, 
            {
                "description": "Fertilization rate was defined as the ratio of normal fertilized oocytes (2PNs) to the number of oocytes used for fertilization (i.e. the denominator in IVF in calculating fertilization rate is all oocytes recovered, but in ICSI it is calculated using only the number of MII oocytes).", 
                "measure": "fertilization rate", 
                "safety_issue": "Yes", 
                "time_frame": "48 hours post IVF/ICSI"
            }, 
            {
                "measure": "implantation rate", 
                "safety_issue": "Yes", 
                "time_frame": "1 month post embryo transfer"
            }
        ], 
        "source": "Nanfang Hospital of Southern Medical University", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "National Natural Science Foundation of China", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Comprehensive Strategic Sciences Cooperation Projects of Guangdong Province and Chinese Academy", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Guangzhou Science and Technology Program key projects", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "National Key Basic Research Development Plan of China", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Chenshiling", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}